BIOPER

A MULTICENTER, INTERNATIONAL, NON-CONTROLLED, PHASE II TRIAL TO IDENTIFY THE MOLECULAR MECHANISMS OF RESISTANCE AND SENSITIVITY TO PALBOCICLIB RE-CHALLENGE UPON PROGRESSION TO A PALBOCICLIB COMBINATION IN ER-POSITIVE METASTATIC BREAST CANCER PATIENTS (BIOPER)

https://clinicaltrials.gov/study/NCT02776137

BREAST

Spain, Italy

Closing

CLINICAL TRIAL DETAILS

THIS IS AN OPEN-LABEL CLINICAL TRIAL WITH TWO DIFFERENT PRIMARY OBJECTIVES: A BIOLOGICAL AND A CLINICAL OBJECTIVE. FROM A CLINICAL POINT OF VIEW, THE OBJECTIVE IS TO ASSESS THE CLINICAL BENEFIT OF THE COMBINATION OF PALBOCICLIB AND HORMONOTHERAPY IN PATIENTS WITH ADVANCE BREAST CANCER THAT HAD PREVIOUSLY RECEIVED ENDOCRINE THERAPY IN COMBINATION WITH PALBOCICLIB AND HAD ACHIEVED CLINICAL BENEFIT DURING PALBOCICLIB TREATMENT WITH SUBSEQUENT DISEASE PROGRESSION. FROM A BIOLOGICAL POINT OF VIEW, THE CHALLENGE IS TO DEFINE A MOLECULAR PROFILE THAT ALLOW IDENTIFYING PATIENTS THAT COULD BENEFIT MORE FROM CONTINUING ON PALBOCICLIB AFTER PROGRESSION ON A PRIOR PALBOCICLIB-CONTAINING REGIMEN.

TUMOR TYPE

PHASE

SITES

COUNTRY

STATUS

PRESS RELEASE

SCIENTIFIC IMPACT

Clinical Cancer Research 2023 publication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811162/ | SABCS 2020 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_7fe9a8d3a2f84426b565c093fc15f745.pdf

BLOG ARTICLES RELATED

Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS: https://www.medsir.org/post/interview-with-dr-llombart-on-oncologytube-on-the-parsifal-and-bioper-studies-presented-at-sabcs | Results of our BIOPER study were presented at SABCS 2020: https://www.medsir.org/post/results-of-our-bioper-study-were-presented-at-sabcs-2020 | SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented: https://www.medsir.org/post/sabcs-2020-final-results-of-parsifal-and-bioper-clinical-trials-to-be-presented | 100% Recruitment Achieved of BioPER study!: https://www.medsir.org/post/100-recruitment-achieved-of-bioper-study | The BioPER study: https://www.medsir.org/post/the-bioper-study

PHERGAIN SITES

Hospital del Mar (Spain) | Institut Català d' Oncologia Badalona (ICO) (Spain) | Hospital Universitario Doce de Octubre (Spain) | Hospital Clínico San Carlos (Spain) | Hospital Universitario La Paz (Spain) | Hospital Clínico Universitario de Valencia (Spain) | Hospital Universitari i Politècnic La Fe (Spain) | Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) | Complejo Hospitalario Universitario A Coruña (CHUAC) (Spain) | Hospital Universitario Virgen del Rocío (Spain) | Hospital Universitario de León (Spain) | Hospital Universitario Reina Sofía (Spain) | Hospital Universitario Miguel Servet (Spain) | Hospital Universitari Vall D'Hebron (Spain) | Hospital Universitari Sant Joan de Reus (Spain) | Instituto Valenciano de Oncología (IVO) (Spain) | CHU de Besançon (Spain listed on site but likely France) | Institut Català d' Oncologia L'Hospitalet (ICO) (Spain) | Ospedale Antonio Perrino (Italy) | Azienda Sanitaria Universitaria Integrata di Udine (Italy) | Instituto Europeo di Oncologia (Italy)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley